PEGylated IGF-I Variants for Neuromuscular Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuromuscular disorders, particularly amyotrophic lateral sclerosis (ALS), face challenges due to the short half-life of insulin-like growth factor 1 (IGF-I), leading to frequent dosing and undesirable side effects, and limited bioavailability, which complicates achieving sustained efficacy.
Innovation Solution
Development of PEGylated IGF-I variants with amino acid alterations at positions 27, 65, and 68, which are characterized by the attachment of polyethylene glycol (PEG) to lysine residues, providing a longer half-life and reduced acute hypoglycemic activity, allowing for higher dosing and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If IGF-I is used for treatment of neuromuscular disorders, then biological activity is achieved, but half-life is short requiring frequent dosing
Solution Approach 1:
The patent creates a composite structure by conjugating IGF-I with polyethylene glycol (PEG) chains to form PEGylated IGF-I variants. This composite material combines the biological activity of IGF-I with the extended circulation properties of PEG, achieving prolonged half-life without sacrificing therapeutic efficacy. The PEG moiety acts as a protective shell that reduces renal clearance and immune recognition, thereby extending the duration of action.
Solution Approach 2:
The patent modifies the molecular parameters of IGF-I by introducing amino acid substitutions (K27R, K65R, K68R) that alter the protein's physical and chemical properties. These parameter changes include reduced renal filtration due to modified charge distribution and enhanced PEGylation efficiency at specific lysine residues, ultimately leading to extended half-life and reduced dosing frequency.
2Reliability
If IGF-I is administered to achieve sustained efficacy, then bioavailability is improved, but acute hypoglycemic side effects occur
Solution Approach 1:
The PEG chain acts as an intermediary between IGF-I and the biological system, modulating the drug's pharmacokinetic and pharmacodynamic properties. This intermediary layer reduces the acute hypoglycemic effect by controlling the release and availability of active IGF-I, while still maintaining sustained efficacy through prolonged circulation. The PEG-IGF-I conjugate provides a buffered delivery mechanism that prevents sudden spikes in IGF-I activity.
3Duration of action of moving object
If PEG is attached to lysine residues to extend half-life, then duration of action is improved, but manufacturing complexity increases
Solution Approach 1:
The patent introduces local quality changes by substituting specific lysine residues (K27, K65, K68) with arginine residues. This creates distinct sites with different chemical properties, allowing controlled and site-specific PEGylation. The local quality modification at these specific positions enables predictable PEG attachment patterns, simplifying the manufacturing process by reducing heterogeneity in the PEGylated product mixture.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the pharmaceutical use of polyethylene glycol-(PEG)ylated IGF-I variants for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS). More specifically, the present invention relates to the use of a PEGylated IGF-I variant for the manufacture of a pharmaceutical composition for the treatment, prevention and/or delay of neuromuscular disorders, in particular ALS wherein the PEGylated IGF-I variant is characterized in that it is derived from the wild- type human IGF-I amino acid sequence (SEQ ID NO: 1) and carries one or two amino acid alterations at amino acid positions 27, 65 and 68 so that one or two of amino acids at positions 27, 65 and 68 is/are a polar amino acid but not lysine and PEG is attached to at least one lysine residue.